Tizanidine
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Using no additional skill — this is a direct content-generation task following the explicit v5 report template already provided in the prompt.
Tizanidine: From Muscle Spasticity to Migraine Disorder
One-Sentence Summary
Tizanidine is a centrally-acting alpha-2 adrenergic agonist traditionally used to manage muscle spasticity. The TxGNN model predicts it may be effective for Migraine Disorder, with 2 clinical trials (including an actively recruiting Phase 3 RCT) and 18 publications currently supporting this direction — though most of the literature is older, indirect (class-level) evidence rather than tizanidine-specific pivotal trial data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Muscle spasticity (globally established use; no TFDA license record — drug not marketed in Taiwan) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.79% |
| Evidence Level | L2 |
| Taiwan Market Status | Not Marketed |
| Number of NDAs (Taiwan) | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Tizanidine is a centrally-acting alpha-2 adrenergic receptor agonist, mechanistically related to clonidine, which reduces presynaptic release of excitatory neurotransmitters. This mechanism is relevant to the central sensitization and muscle-tension-related pathophysiology implicated in migraine and chronic daily headache. Clinically, low-dose tizanidine combined with NSAIDs has already been used in practice for detoxification from analgesic-overuse (rebound) headache, providing an established real-world precedent for its use in headache disorders.
The original indication (spasticity) and the predicted indication (migraine) share a common pharmacological thread: alpha-2 agonists as a drug class (clonidine, guanfacine, tizanidine) modulate central noradrenergic/excitatory tone, and several agents in this class have documented use in neurological and headache-related conditions. This makes the repurposing hypothesis a reasonable pharmacological extrapolation rather than a novel, unprecedented mechanism — a conclusion reinforced by decades-old open-label and placebo-controlled studies of tizanidine in chronic daily headache prophylaxis (see literature below).
Currently, detailed formal mechanism-of-action documentation from DrugBank is flagged as a data gap in this evidence pack (DG002); the mechanistic description above is derived from the model’s repurposing rationale rather than a structured MOA record.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05484349 | Phase 3 | Recruiting | 189 | Multicenter, randomized, double-blind, placebo-controlled trial evaluating oral tizanidine for prevention of migraine attacks (with/without aura) in adults 18–65; no results reported yet |
| NCT02403687 | N/A | Completed | 300 | 24-week observational study on topical NSAIDs for pain relief; not tizanidine-specific, only broadly relevant to analgesic efficacy research |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12167135 | 2002 | RCT | Headache | Double-blind, placebo-controlled, multicenter trial of tizanidine as adjunctive prophylaxis for chronic daily headache (incl. chronic migraine) |
| 11318882 | 2001 | Open-label study | Headache | Open-label dose-titration study of tizanidine tablets for prophylaxis of chronic daily headache |
| 11903539 | 2002 | Cohort | Headache | Outpatient regimen using low-dose tizanidine with NSAIDs for detoxification from analgesic rebound headache |
| 40983294 | 2025 | Preclinical/Formulation | J Control Release | Supramolecular cocrystal of tizanidine + meloxicam shows synergistic anti-migraine efficacy in preclinical formulation study |
| 12696998 | 2003 | Review | CNS Drugs | Reviews muscle-tone-modifying agents (baclofen, tizanidine, botulinum toxin A) as preventive treatments for migraine and tension-type headache |
| 21770931 | 2011 | Review | Headache | Reviews chronic migraine prophylactic agents (incl. tizanidine) in the context of medication-overuse trials |
| 23293866 | 2013 | Review | Headache | Rational approach to chronic migraine management, listing tizanidine among established prophylactic options |
| 17115988 | 2006 | Review | Headache | Review of chronic daily headache prophylaxis, citing tizanidine evidence alongside topiramate/gabapentin |
| 15115635 | 2004 | Review | Curr Pain Headache Rep | Reviews emerging migraine prophylactic treatments, including tizanidine |
| 20464578 | 2010 | Review | Neurol Sci | Systematic review of double-blind, placebo-controlled pharmacological prophylaxis trials for chronic migraine |
Taiwan Market Information
Tizanidine currently holds no TFDA license and is not marketed in Taiwan (market_status: 未上市, total_licenses: 0). No product/dosage-form data is available for this evidence pack.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack (TFDA label data is flagged as a blocking data gap, DG001), and the DDI database query returned no results.
Conclusion and Next Steps
Decision: Hold
Rationale: The alpha-2 agonist mechanism and older placebo-controlled/open-label studies provide plausible, but dated and indirect, support for tizanidine in chronic daily headache/migraine prophylaxis. The one directly relevant, adequately powered study (NCT05484349, Phase 3) is still recruiting with no results yet, and a blocking safety data gap (TFDA warnings/contraindications) prevents even an initial safety screening (S1).
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — blocking gap, DG001
- Structured mechanism-of-action data from DrugBank — DG002
- Results of NCT05484349 upon completion
- DDI dataset re-query, as current search returned no interactions on record
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.